Pharmaceutical CAS 877399-52-5 Crizotinib Raw Material Powder Crizotinib Intermediate Crizotinib

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Model NO.: D-sung Crizotinib
• Product Name: Crizotinib
• Name: Crizotinib Powder
• Appearance: White or off-White Crystalline Powder
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Anti-Cancer
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 877399-52-5
• Mf: C21h22cl2fn5o
• MW: 450.34
• Density: 1.475
• Melting Point: 197-203 C
• Boiling Point: 599.177 C at 760 Mmhg
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-sung
• Origin: Shaanxi Xi′an
• Production Capacity: 500kg/Month

Product Description

Pharmaceutical CAS 877399-52-5 Crizotinib Raw Material Powder Crizotinib Intermediate Crizotinib

 

Product Description

Product Details

Product Name	Crizotinib
CAS No.	877399-52-5
MF	C21H22Cl2FN5O
MW	450.34
Appearance and shape	White or off-white crystalline powder

Crizotinib (XalkoriR), chemically known as 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]pyridin-2-amine,is a white to light yellow powder. Crizotinib is an anti-cancer drug, It is primarily useful for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who are positive for mesenchymal lymphoma kinase (ALK) as determined by an SFDA-approved assay.

Application & Function

Function
Crizotinib has an aminopyridine structure, and functions as a protein kinase inhibitor by competitive binding within the ATP-binding pocket of target kinases. About 4% of patients with non-small cell lung carcinoma have a chromosomal rearrangement that generates a fusion genebetween EML4 ('echinoderm microtubule-associated protein-like 4') andALK ('anaplastic lymphoma kinase'), which results in constitutivekinase activity that contributes to carcinogenesis and seems to drive the malignant phenotype. The kinase activity of the fusion protein is inhibited by crizotinib. Patients with this gene fusion are typically younger non-smokers who do not have mutations in either theepidermal growth factor receptor gene (EGFR) or in the K-Ras gene.The number of new cases of ALK-fusion NSLC is about 9,000 per year in the U.S. and about 45,000 worldwide
Application
1.Treating certain types of lung cancer. It may also be used for other conditions as determined by your doctor.
2.Crizotinib is a tyrosine kinase inhibitor. It works by preventing the growth of cancer cells.
3.Crizotinib inhibits the c-Met/Hepatocyte growth factor receptor (HGFR) tyrosine kinase, which is involved in the oncogenesis of a number of other histological forms of malignant neoplasms.
4.Crizotinib is currently thought to exert its effects through modulation of the growth, migration, and invasion of malignant cells.Other studies suggest that crizotinib might also act via inhibition of angiogenesis in malignant tumors.

Specification